Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Dewdney

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of the National Cancer Institute|June 25, 2014
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trialFrancesco Sclafani, David Gonzalez, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
Diagnostic and Prognostic Research|August 3, 2022
Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 studyStelios Theophanous, Per-Ivar Lønne, Ananya Choudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal CancerChristopher J M Williams, Faye Elliott, Nancy Sapanara, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of the National Cancer Institute|June 25, 2014
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trialFrancesco Sclafani, David Gonzalez, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
Diagnostic and Prognostic Research|August 3, 2022
Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 studyStelios Theophanous, Per-Ivar Lønne, Ananya Choudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal CancerChristopher J M Williams, Faye Elliott, Nancy Sapanara, et al.
Pageof 2